AMTB vs HBNC

AMTB exhibits mixed financial health with a Piotroski F-Score of 4/9, indicating stable but not strong fundamentals. The absence of an Altman Z-Score prevents a full distress risk assessment, though the Price/Book of 0.93 suggests the stock trades below tangible book value. Strong revenue growth of 576.5% YoY and a low forward P/E of 7.88 signal potential value, but weak ROA of 0.64% and inconsistent earnings surprises temper optimism. Analysts recommend a 'buy' with a $22.75 target, implying modest upside from current levels.

HBNC presents a stark contrast between poor fundamental health and attractive valuation. The Piotroski F-Score of 2/9 indicates significant financial weakness, further evidenced by a negative ROE of -20.73% and ROA of -2.11%. While the forward P/E of 8.08 and analyst target of $20.80 suggest value, the disconnect between massive revenue growth (218.7%) and declining EPS growth (-18.5%) suggests inefficient scaling or high acquisition costs. The stock is currently a high-risk value play with deteriorating internal health metrics.